StoryTest
REC-4881 Phase 2 interim data: 75% response rate and 43% median polyp reduction in familial adenomatous polyposis
Recursion reported interim Phase 2 efficacy data from the TUPELO trial of REC-4881, an AI-designed MEK1/2 inhibitor for familial adenomatous polyposis. At week 13, 75% of evaluable patients showed polyp burden reduction with a median decrease of 43%; durability was demonstrated at week 25, where 82% of responders maintained their response with median 53% reduction. This represents the first clinical proof that Recursion's AI platform can translate from biological discovery to patient benefit.
- Phase 2 interim analysis showed 75% of patients achieved polyp burden reduction by week 13, with median 43% decrease
- At week 25, 82% of responders maintained benefit with median 53% polyp reduction, demonstrating durability
- TUPELO enrolls patients age 18+ with familial adenomatous polyposis and residual polyps, including dose-escalation cohorts
- Results support a path toward FDA registration meeting to define a Phase 3 strategy
- First REC program to provide clinical validation of Recursion's full-stack AI drug-discovery platform